Skip to content
DefDex
Santero Therapeutics logo

Startup · Belgium

Santero Therapeutics

HQ Charleroi, BelgiumFounded 202111-50 employeesUpdated

Develops medicines targeting persistent bacterial infections.

Website

Funding1 round · ~$8.7M

Equity raised
~$8.7M
Latest
~$8.7MSeries A · Jun 8, 2023

Raised counts equity rounds; debt, secondary sales and grants are totaled separately. Amounts in other currencies are converted at the announcement month's average rate. A ~ marks an estimated or converted amount.

People
PersonRole
Abel Garcia-PinoFounder
Cédric GovaertsFounder

Sources4

Profile2

  1. 1

    Defence Finance Monitor · Supports Organization · description

    “Its technology aligns with Europe’s biotechnology and health security priorities by introducing a first-in-class mechanism that targets bacterial stress response”
  2. 2

    Supports Organization · name

    “These patients need a fundamentally different approach. One master switch. Two mechanisms. A platform for chronic refractory disease. Santero Therapeutics”

Funding1

  1. 3

    bouncewatch.com · Supports Funding round · amount, Organization · ownership

    “Santero Therapeutics secured a significant €8.00M Series A investment on 08 June 2023. The investment was led by Newton BioCapital, Sambrinvest, SFPIM, Pierre Drion, and S.R.I.W.”

People1

  1. 4

    Octen Business Search · Supports Organization · country, Organization · employee range, Organization · founded year, Organization · hq city, Organization · hq region, Organization · linkedin url, Role

    “country: BE (profile: Rue Clément Ader 10, Charleroi, Walloon Region 6041, BE)”

Each fact on this page is attached to the sources that support it. Archived copies are linked when we keep one.